<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781844</url>
  </required_header>
  <id_info>
    <org_study_id>SHP634-101</org_study_id>
    <secondary_id>2015-004757-40</secondary_id>
    <nct_id>NCT02781844</nct_id>
  </id_info>
  <brief_title>Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Subjects With Hypoparathyroidism</brief_title>
  <acronym>PARALLAX</acronym>
  <official_title>An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to characterize the effects of twice daily administration of
      rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and
      tolerability over the course of 24 hours as compared with the current once daily dosing
      regimen of marketed rhPTH(1-84) (marketed in the United States as Natpara®).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pharmacokinetic profile of rhPTH(1-84) as measured by plasma PTH concentrations</measure>
    <time_frame>Baseline up to a maximum of 65 days</time_frame>
    <description>Assessment will be based on the effects of the subcutaneous doses of 25μg administered twice-daily, 50μg administered twice-daily, and 100μg administered once-daily, as well as the effect of supplemental oral calcium intake, in subjects with hypoparathyroidism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacodynamic effects of rhPTH(1-84) ± supplemental calcium as measured by control of serum calcium</measure>
    <time_frame>Baseline up to a maximum of 65 days</time_frame>
    <description>Assessment will be based on the effects of the subcutaneous doses of 25μg administered twice-daily, 50μg administered twice-daily, and 100μg administered once-daily, as well as the effect of supplemental oral calcium intake, in subjects with hypoparathyroidism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacodynamic effects of rhPTH(1-84) ± supplemental calcium as measured by urinary calcium excretion</measure>
    <time_frame>Baseline up to a maximum of 65 days</time_frame>
    <description>Assessment will be based on the effects of the subcutaneous doses of 25μg administered twice-daily, 50μg administered twice-daily, and 100μg administered once-daily, as well as the effect of supplemental oral calcium intake, in subjects with hypoparathyroidism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of rhPTH(1-84) as measured by AEs and SAEs</measure>
    <time_frame>Baseline to Follow-up (approx. 2 months)</time_frame>
    <description>AEs and SAEs will be measured by any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal (investigational) product</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>A/B or B/A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F/E or E/F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mcg rhPTH(1-84)</intervention_name>
    <description>25mcg</description>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_label>A/B or B/A</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50mcg rhPTH(1-84)</intervention_name>
    <description>50mcg</description>
    <arm_group_label>F/E or E/F</arm_group_label>
    <arm_group_label>C/B or B/C</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mcg rhPTH(1-84)</intervention_name>
    <description>100mcg</description>
    <arm_group_label>F/E or E/F</arm_group_label>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_label>A/B or B/A</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhpth(1-84)</intervention_name>
    <description>rhpth(1-84)</description>
    <arm_group_label>F/E or E/F</arm_group_label>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_label>A/B or B/A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. History of hypoparathyroidism

          2. Requirement for supplemental oral calcium treatment ≥ 1000 mg per day.

          3. Requirement for active vitamin D therapy at a dose of ≥ 0.25 mcg per day . (i.e., ≥
             0.25 mcg calcitriol or equivalent per day).

          4. Serum calcium levels within the laboratory normal range based on clinical chemistry
             lab results at Screening (central and/or local lab) and Treatment Period 1, Day -2
             (central and/or local lab) or, if outside the normal range, considered as not
             significant by the Investigator.

          5. Urinary calcium excretion ≥200 mg (5mmol)/24h, based on a 24-hour collection prior to
             check-in to the CRC at Treatment Period 1, Day -2 (central and/or local lab).

          6. Serum magnesium level within the laboratory normal range at the screening examination
             or, if outside the normal range, considered as not significant by the Investigator.

          7. Serum thyroid function tests within normal laboratory limits at screening, or if
             outside of the normal range, considered as not clinically significant by the
             Investigator.

          8. Serum 25(OH) D level between the lower limit of normal and 1.5 fold the laboratory
             upper limit of normal at the first screening visit or, if outside the normal range,
             considered as not significant by the Investigator.

          9. Serum creatinine &lt; 1.5 mg/dL (&lt;133 micromol/L) AND creatinine clearance &gt; 60 mL/
             minute(&gt;1.002mL/s).

        Key Exclusion Criteria:

          1. Participation in any other investigational drug study within the last 3 months

          2. Use of any of the following prior to study drug administration:

        (1) 14 days: thiazide diuretics (2) 30 days: loop diuretics, lithium, , systemic
        corticosteroid (3) 3 months: calcitonin, cinacalcet hydrochloride, rhPTH(1-84) or
        N-terminal PTH or PTH-related peptide fragments or analogs (4) females only; changes in
        hormone replacement therapy within 3 months (5) 6 months: fluoride tablets, oral
        bisphosphonates, methotrexate growth hormone, digoxin; raloxifene or similar selective
        estrogen receptor modulators (6) 12 months: intravenous bisphosphonates, drug or alcohol
        abuse 3. History of a clinically significant disorder involving the cardiovascular,
        respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine (with exception
        of the condition under study), or neurologic system(s) or psychiatric disease as determined
        by the Investigator.

        4. Known history of hypoparathyroidism resulting from an activating mutation in the calcium
        sensing receptor (CaSR) gene or impaired responsiveness to PTH (pseudohypoparathyroidism).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>1 866-842-5335</phone>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalia Kuko, MD</last_name>
      <email>dkuko@providenceclinical.com</email>
    </contact>
    <investigator>
      <last_name>Teresa Sligh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munro Peacock</last_name>
      <phone>317-274-4356</phone>
      <email>MPEACOCK@IU.EDU</email>
    </contact>
    <investigator>
      <last_name>Munro Peacock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research Center</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Wise, MD</last_name>
      <email>jwisemd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jonathon Wise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Clarke, MD</last_name>
      <email>roberson.tamera@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bart Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mishaela Rubin, MD</last_name>
      <email>mrr6@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mishaela Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Anaya</last_name>
      <phone>614-688-6257</phone>
      <email>amber.anaya@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Ing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intekhab Ahmed, MD</last_name>
      <phone>215-955-8405</phone>
      <email>marsha.simmons@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Intekhab Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NOCCR</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Gibson</last_name>
      <phone>865-305-9100</phone>
      <email>sigibson@noccr.com</email>
    </contact>
    <investigator>
      <last_name>William Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.parallaxstudy.com/?utm_source=ClinicalTransparency+&amp;utm_medium=EmailResponse&amp;utm_campaign=ContactClinicalTransparency</url>
    <description>Study Website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

